Oncology/Hematology Archives | 第 6 页，共 12 页 | Certara

Blog

Using M&S to Evaluate Oncology Drug Dosing

There are numerous challenges in developing oncology drugs: (1) they are often very toxic which…

Maria Saluta2018 年 4 月 13 日

Publication

An Analysis on Distribution and Inter-relationships of Biomarkers Under Rivaroxaban in Japanese Patients with Non-valvular Atrial Fibrillation (CVI ARO 1)

webdev2018 年 3 月 15 日

Publication

A Randomized, Controlled Trial Evaluating the Efficacy and Safety of BTH1677 in Combination with Bevacizumab, Carboplatin, and Paclitaxel in First-line Treatment of Advanced Non-small Cell Lung Cancer

webdev2018 年 2 月 27 日

Publication

Incorporation of GSTA1 Genetic Variations into a Population Pharmacokinetic Model for IV Busulfan in Pediatric Hematopoietic Stem Cell Transplantation

webdev2018 年 2 月 22 日

Blog

勘测全球范围监管申请建模与模拟的现状

Analogous to how a geologist surveys the “lay of the land” to determine if oil…

Maria Saluta2018 年 2 月 16 日

Publication

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

webdev2018 年 2 月 15 日

Publication

Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

webdev2017 年 11 月 1 日

Publication

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach

webdev2017 年 9 月 15 日

Publication

Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types

webdev2017 年 8 月 1 日

Publication

Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

webdev2017 年 7 月 15 日

© 2025 Certara. 保留所有权力。 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software